

LIVERFAST™

A Comprehensive MASLD/MASH Solution

SCREENING

Ruling out with certainty



CLINICAL PATHWAY

Works great with VCTE

IDENTIFICATION

Reliably finding at-risk patients

MONITORING

Tracking therapy in real-time

SIMPLE AND EASY TO DO



01

Physician prescribes LIVERFAST



02

Lab analyzes 10 biomarkers from 1 blood sample



03

Biomarker values plus age, height, weight and gender entered into platform



04

LIVERFAST results available immediately

1 BLOOD DRAW ► 3 SCORES ► 5 ADVANTAGES




- Total Cholesterol
- Tryglycerides
- GGT
- ALT
- AST
- Total Bilirubin
- Glucose
- Alpha-2-Macroglobulin
- Haptoglobin
- Apolipoprotein A1

SERUM BIOMARKERS

AGE + GENDER

BMI

ADVANCED ANALYTICS
+ SCORING
+ STAGING



Improving Identification For Better Liver Care

From Silent Risk to Early Identification

Early identification is the foundation of effective liver disease management.

FIND THE "INVISIBLE" PATIENTS

Many patients with metabolic risk factors have significant liver disease despite normal or mildly elevated liver enzymes. LIVERFAST helps uncover these hidden cases.

DETECT RISK EARLIER

By combining multiple biomarkers and patient parameters, LIVERFAST identifies patients at risk before advanced disease develops

RELIABLE IN HIGH-RISK POPULATIONS


Maintains strong performance in populations where MASLD is most prevalent:

- Type 2 diabetes
- High BMI
- Age >65
- Cardiometabolic disease


CLEAR STRATIFICATION

Provides definitive staging across fibrosis categories, helping clinicians identify patients who require closer monitoring or specialist referral

Target for Identification




LIVERFAST Capabilities for Identification



Complex algorithms yield a singular, actionable coordinate.

Precision Staging Across the MASLD Fibrosis Spectrum



FIB-4 Sensitivity for ≥F3: **37.3%**

Often yields inconclusive results, leaving patients unstaged

Fibrosis Stage	LIVERFAST Identified	FIB-4 Identified
F2/F3 (Treatable)	107	17
F4 (Cirrhosis)	67	45
AUROC (≥ F3 Performance)	0.874	0.821

LIVERFAST Sensitivity for ≥F3: **65.5%**

Eliminates the "Indeterminate" Grey Zone by providing specific staging (F0-F4)

LIVERFAST Enables Earlier and Better Action

Identified risk → Confirmed disease stage → Confident Medical Decisions

EARLY IDENTIFICATION ALLOWS CLINICIANS TO:

- 01 Initiate lifestyle or pharmacologic interventions earlier
- 02 Monitor patients before disease progression
- 03 Refer appropriate patients for specialist evaluation
- 04 Improve long-term liver outcomes



Part of Fibronostics' complete liver care framework:

Screening | Monitoring | Clinical Pathway |
Ease of Use | **Identification**

Clear Answers for MASLD/MASH Care.

Contact Us
888-552-1603 | service@fibronostics.com

www.fibronostics.com



FIBRONOSTICS US, INC.
615 Baronne St, Suite 100 New Orleans LA 70113